All In Biotech

Drug Trial Radar · NCT05489614

A Study to Evaluate the Pharmacokinetics, Safety, and Pharmacodynamics of Olpasiran in Participants With Normal Renal Function and Participants With Various Degrees of Renal Impairment

A Phase I, Open-label, Single-Dose Study to Evaluate the Pharmacokinetics, Safety, and Pharmacodynamics of Olpasiran in Subjects With Normal Renal Function and Subjects With Various Degrees of Renal Impairment

Last checked: Nov 19, 2026Latest source record: Oct 23, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

33

Actual

Start

Sep 13, 2022

Primary completion

Oct 24, 2023

Study completion Dec 19, 2023

Sponsor

Lead sponsor
AmgenAmgen (AMGN)
Sponsor type
Industry
First posted
Aug 5, 2022

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Non randomized
Model
Parallel
Masking
None
Primary purpose
Basic science
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 75 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

The primary objective of this study is to evaluate the pharmacokinetics (PK) of a single dose of olpasiran in participants with normal renal function and participants with various degrees of renal impairment.

Conditions

  • Renal Impairment

Interventions

  • OlpasiranDrug

    Participants will receive olpasiran by subcutaneous (SC) injection.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Maximum Observed Serum Concentration (Cmax) of OlpasiranTime frame: Predose, 0.5, 1, 3, 6, 9, 12, 24, 36, 48, 72, 96, 144 hours (postdose), Day 15, and Day 29
  2. Area Under the Plasma Concentration-time Curve from Time Zero to the Last Quantifiable Concentration (AUClast) of OlpasiranTime frame: Predose, 0.5, 1, 3, 6, 9, 12, 24, 36, 48, 72, 96, 144 hours (postdose), Day 15, and Day 29
  3. Area Under the Plasma Concentration-time Curve from Time Zero to Infinity (AUCinf) of OlpasiranTime frame: Predose, 0.5, 1, 3, 6, 9, 12, 24, 36, 48, 72, 96, 144 hours (postdose), Day 15, and Day 29
  4. Dialysis Clearance of Drug From Plasma (CLD) of OlpasiranTime frame: Pre-Dialysis, 0.5, 1, 3 hours after the start of Dialysis, and immediately following the end of Dialysis, Day 1, Day 4

Locations

6 sites in 1 country. Site status is shown where the registry gives one.

  • Inland Empire Clinical Trials, LLC

    Rialto, California

  • CRSCA HC LLC, dba Creekside Post Acute

    Yucaipa, California

  • Clinical Pharmacology Of Miami, LLC

    Miami, Florida

  • Advanced Pharma CR, LLC

    Miami, Florida

  • Orlando Clinical Research Center

    Orlando, Florida

  • Nucleus Network - Minneapolis

    Saint Paul, Minnesota

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.